A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Lind, M. J., Cantwell, B. M., Millward, M. J., Robinson, A., Proctor, M., Simmons, D., Carmichael, J., Harris, A. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977567/
https://www.ncbi.nlm.nih.gov/pubmed/1314071
_version_ 1782135289657950208
author Lind, M. J.
Cantwell, B. M.
Millward, M. J.
Robinson, A.
Proctor, M.
Simmons, D.
Carmichael, J.
Harris, A. L.
author_facet Lind, M. J.
Cantwell, B. M.
Millward, M. J.
Robinson, A.
Proctor, M.
Simmons, D.
Carmichael, J.
Harris, A. L.
author_sort Lind, M. J.
collection PubMed
description Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated. There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further evaluated.
format Text
id pubmed-1977567
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19775672009-09-10 A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Lind, M. J. Cantwell, B. M. Millward, M. J. Robinson, A. Proctor, M. Simmons, D. Carmichael, J. Harris, A. L. Br J Cancer Research Article Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated. There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further evaluated. Nature Publishing Group 1992-04 /pmc/articles/PMC1977567/ /pubmed/1314071 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Lind, M. J.
Cantwell, B. M.
Millward, M. J.
Robinson, A.
Proctor, M.
Simmons, D.
Carmichael, J.
Harris, A. L.
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title_full A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title_fullStr A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title_full_unstemmed A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title_short A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
title_sort phase ii trial of goserelin (zoladex) in relapsed epithelial ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977567/
https://www.ncbi.nlm.nih.gov/pubmed/1314071
work_keys_str_mv AT lindmj aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT cantwellbm aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT millwardmj aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT robinsona aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT proctorm aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT simmonsd aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT carmichaelj aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT harrisal aphaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT lindmj phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT cantwellbm phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT millwardmj phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT robinsona phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT proctorm phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT simmonsd phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT carmichaelj phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer
AT harrisal phaseiitrialofgoserelinzoladexinrelapsedepithelialovariancancer

Ejemplares similares